Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6436 to 6450 of 8314 results

  1. Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    22 December 2016

  2. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Evidence summary
    Published
    2 December 2020

  3. Actinic keratosis: ingenol mebutate gel (ESNM14)

    This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.

    Evidence summary
    Published
    19 March 2013

  4. Schizophrenia: lurasidone (ESNM15)

    This evidence summary has been replaced by ESNM48

    Evidence summary
    Published
    9 April 2013

  5. Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

    This evidence summary has been updated and replaced by NICE guideline CG61.

    Evidence summary
    Published
    9 April 2013

  6. Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Evidence summary
    Published
    16 April 2013

  7. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Evidence summary
    Published
    23 May 2013

  8. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Evidence summary
    Published
    7 May 2013

  9. Idiopathic overactive bladder syndrome: botulinum toxin A (ESNM2)

    This evidence summary has been replaced by NICE guideline CG171.

    Evidence summary
    Published
    1 September 2012

  10. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    21 May 2013

  11. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    18 June 2013

  12. Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    25 June 2013

  13. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

    Evidence summary
    Published
    23 July 2013

  14. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Evidence summary
    Published
    10 September 2013

  15. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    24 September 2013